Current progress in development of hepatitis C virus vaccines

T. Jake Liang

Research output: Contribution to journalArticle

Abstract

Despite major advances in the understanding and treatment of hepatitis C, a preventive vaccine remains elusive. The marked genetic diversity and multiple mechanisms of persistence of hepatitis C virus, combined with the relatively poor immune response of the infected host against the virus, are major barriers. The lack of robust and convenient model systems further hampers the effort to develop an effective vaccine. Advances in our understanding of virus-host interactions and protective immunity in hepatitis C virus infection provide an important roadmap to develop potent and broadly directed vaccine candidates targeting both humoral and cellular immune responses. Multiple approaches to generating and testing viral immunogens have met with variable success. Several candidates have advanced to clinical trials based on promising results in chimpanzees. The ultimate path to a successful preventive vaccine requires comprehensive evaluations of all aspects of protective immunity, innovative application of state-of-the-art vaccine technology and properly designed vaccine trials that can affirm definitive endpoints of efficacy.

Original languageEnglish (US)
Pages (from-to)869-878
Number of pages10
JournalNature Medicine
Volume19
Issue number7
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Viruses
Hepacivirus
Vaccines
Immunity
Pan troglodytes
Virus Diseases
Hepatitis C
Humoral Immunity
Cellular Immunity
Clinical Trials
Technology
Testing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Current progress in development of hepatitis C virus vaccines. / Liang, T. Jake.

In: Nature Medicine, Vol. 19, No. 7, 07.2013, p. 869-878.

Research output: Contribution to journalArticle

Liang, T. Jake. / Current progress in development of hepatitis C virus vaccines. In: Nature Medicine. 2013 ; Vol. 19, No. 7. pp. 869-878.
@article{5b8a4f7d44174b52a0c45f50e93fa4e6,
title = "Current progress in development of hepatitis C virus vaccines",
abstract = "Despite major advances in the understanding and treatment of hepatitis C, a preventive vaccine remains elusive. The marked genetic diversity and multiple mechanisms of persistence of hepatitis C virus, combined with the relatively poor immune response of the infected host against the virus, are major barriers. The lack of robust and convenient model systems further hampers the effort to develop an effective vaccine. Advances in our understanding of virus-host interactions and protective immunity in hepatitis C virus infection provide an important roadmap to develop potent and broadly directed vaccine candidates targeting both humoral and cellular immune responses. Multiple approaches to generating and testing viral immunogens have met with variable success. Several candidates have advanced to clinical trials based on promising results in chimpanzees. The ultimate path to a successful preventive vaccine requires comprehensive evaluations of all aspects of protective immunity, innovative application of state-of-the-art vaccine technology and properly designed vaccine trials that can affirm definitive endpoints of efficacy.",
author = "Liang, {T. Jake}",
year = "2013",
month = "7",
doi = "10.1038/nm.3183",
language = "English (US)",
volume = "19",
pages = "869--878",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Current progress in development of hepatitis C virus vaccines

AU - Liang, T. Jake

PY - 2013/7

Y1 - 2013/7

N2 - Despite major advances in the understanding and treatment of hepatitis C, a preventive vaccine remains elusive. The marked genetic diversity and multiple mechanisms of persistence of hepatitis C virus, combined with the relatively poor immune response of the infected host against the virus, are major barriers. The lack of robust and convenient model systems further hampers the effort to develop an effective vaccine. Advances in our understanding of virus-host interactions and protective immunity in hepatitis C virus infection provide an important roadmap to develop potent and broadly directed vaccine candidates targeting both humoral and cellular immune responses. Multiple approaches to generating and testing viral immunogens have met with variable success. Several candidates have advanced to clinical trials based on promising results in chimpanzees. The ultimate path to a successful preventive vaccine requires comprehensive evaluations of all aspects of protective immunity, innovative application of state-of-the-art vaccine technology and properly designed vaccine trials that can affirm definitive endpoints of efficacy.

AB - Despite major advances in the understanding and treatment of hepatitis C, a preventive vaccine remains elusive. The marked genetic diversity and multiple mechanisms of persistence of hepatitis C virus, combined with the relatively poor immune response of the infected host against the virus, are major barriers. The lack of robust and convenient model systems further hampers the effort to develop an effective vaccine. Advances in our understanding of virus-host interactions and protective immunity in hepatitis C virus infection provide an important roadmap to develop potent and broadly directed vaccine candidates targeting both humoral and cellular immune responses. Multiple approaches to generating and testing viral immunogens have met with variable success. Several candidates have advanced to clinical trials based on promising results in chimpanzees. The ultimate path to a successful preventive vaccine requires comprehensive evaluations of all aspects of protective immunity, innovative application of state-of-the-art vaccine technology and properly designed vaccine trials that can affirm definitive endpoints of efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84880301028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880301028&partnerID=8YFLogxK

U2 - 10.1038/nm.3183

DO - 10.1038/nm.3183

M3 - Article

C2 - 23836237

AN - SCOPUS:84880301028

VL - 19

SP - 869

EP - 878

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -